Last reviewed · How we verify
Zeria (EFONIDIPINE)
Zeria (generic name: EFONIDIPINE) is a drug. It is currently in Phase 2 development for Hypertensive disorder.
Zeria works by blocking the T-type calcium channel, which helps to relax blood vessels and lower blood pressure.
Zeria (Efondipine) is a small molecule modality targeting the voltage-dependent T-type calcium channel subunit alpha-1H. It is used to treat hypertensive disorders. The commercial status of Zeria is currently unknown, and it is not clear if it is patented or available as a generic. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacological profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | EFONIDIPINE |
|---|---|
| Target | Voltage-dependent T-type calcium channel subunit alpha-1H |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Think of your blood vessels like a garden hose. When the T-type calcium channel is active, it's like someone is squeezing the hose, making it harder for blood to flow. By blocking this channel, Zeria helps to relax the blood vessels, making it easier for blood to flow and lowering blood pressure.
Approved indications
- Hypertensive disorder
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zeria CI brief — competitive landscape report
- Zeria updates RSS · CI watch RSS
Frequently asked questions about Zeria
What is Zeria?
How does Zeria work?
What is Zeria used for?
What is the generic name of Zeria?
What development phase is Zeria in?
What does Zeria target?
Related
- Target: All drugs targeting Voltage-dependent T-type calcium channel subunit alpha-1H
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertensive disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing